- Home
- SWIN vs BLRX Comparison
SWIN vs BLRX Comparison
Compare SWIN & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIN
- BLRX
- Stock Information
- Founded
- SWIN 2017
- BLRX 2003
- Country
- SWIN Hong Kong
- BLRX Israel
- Employees
- SWIN N/A
- BLRX N/A
- Industry
- SWIN
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SWIN
- BLRX Health Care
- Exchange
- SWIN Nasdaq
- BLRX Nasdaq
- Market Cap
- SWIN 41.7M
- BLRX 36.0M
- IPO Year
- SWIN 2023
- BLRX 2011
- Fundamental
- Price
- SWIN $1.76
- BLRX $0.20
- Analyst Decision
- SWIN
- BLRX Strong Buy
- Analyst Count
- SWIN 0
- BLRX 2
- Target Price
- SWIN N/A
- BLRX $5.50
- AVG Volume (30 Days)
- SWIN 101.5K
- BLRX 1.7M
- Earning Date
- SWIN 01-03-2025
- BLRX 11-25-2024
- Dividend Yield
- SWIN N/A
- BLRX N/A
- EPS Growth
- SWIN N/A
- BLRX N/A
- EPS
- SWIN N/A
- BLRX N/A
- Revenue
- SWIN $3,437,000.00
- BLRX $21,991,000.00
- Revenue This Year
- SWIN $165,742.30
- BLRX N/A
- Revenue Next Year
- SWIN $29.12
- BLRX N/A
- P/E Ratio
- SWIN N/A
- BLRX N/A
- Revenue Growth
- SWIN N/A
- BLRX N/A
- 52 Week Low
- SWIN $1.70
- BLRX $0.19
- 52 Week High
- SWIN $72.55
- BLRX $1.68
- Technical
- Relative Strength Index (RSI)
- SWIN 28.20
- BLRX 25.94
- Support Level
- SWIN $1.70
- BLRX $0.23
- Resistance Level
- SWIN $2.09
- BLRX $0.56
- Average True Range (ATR)
- SWIN 0.18
- BLRX 0.03
- MACD
- SWIN -0.05
- BLRX 0.00
- Stochastic Oscillator
- SWIN 7.14
- BLRX 11.82
About SWIN Solowin Holdings
Solowin Holdings Ltd is a investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secured one-stop electronic platform. It is engaged in providing securities related services, investment advisory service, and asset management service to customers. The operations were organized into four reportable segments: securities related services, investment advisory services, corporate consultancy services, and asset management services. It derives maximum revenue from investment advisory services.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.